• Explore /
  • Poster
  • / SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.

SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.

Abstract Poster

Authors

null

Yuqin Song

Key Laboratory of Carcinogenesis and Transitional Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China

Yuqin Song , Yanyan Liu , Zhi-Ming Li , Lanfang Li , Hang Su , Zhengming Jin , Xuelan Zuo , Jianyuan Wu , Hui Zhou , Kunyan Li , Chuan He , Jianfeng Zhou , Junyuan Qi , Siguo Hao , Zhen Cai , Yijing Li , Weiwei Wang , Xiaojing Zhang , Jianjun Zou , Jun Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

NCT03603951

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7525)

DOI

10.1200/JCO.2022.40.16_suppl.7525

Abstract #

7525

Poster Bd #

179

Abstract Disclosures

Similar Posters

First Author: Marjorie Glass Zauderer

First Author: Steven M. Horwitz

First Author: Umberto Vitolo

First Author: Joanna S. Yi